Business
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool formation, gut hydration, and bowel healthExpansion builds on Jaguar's focus on sustainably derived, plant-based gastrointestinal products for people and animals SAN FRANCISCO, CA / ACCESS Newswire / May 4, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\") today announced the planned launch of Neonorm Dog, a new extension of the Company's Neonorm franchise for companion animals. Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to support normal stool formation, gut hydration, and bowel health in dogs. The Neonorm franchise currently includes Neonorm Foal and Neonorm Calf, plant-based products developed to support proper hydration and bowel health in pre-weaned foals and calves. Neonorm products contain a standardized botanical extract derived from the sustainably harvested Croton lechleri tree, act locally in the gut.\"We believe Neonorm Dog represents a natural and strategically important expansion of the Neonorm franchise,\" said Lisa Conte, Jaguar's founder, president, and CEO. \"Dog owners are increasingly seeking products that are plant-based, non-antibiotic, and easy to incorporate into the management of digestive health. With Neonorm Dog, we expect to make the benefits of the Neonorm platform available to a much broader group of animals and pet owners.\"Jaguar's animal health strategy is focused on gastrointestinal products for companion and production animals. The Company's prescription animal health product Canalevia-CA1 is conditionally approved by FDA for the treatment of chemotherapy-induced diarrhea in dogs, and Jaguar recently announced statistically significant topline results from an effectiveness trial of crofelemer for treatment of chemotherapy-induced diarrhea in dogs, which the Company expects to support its advancement toward full FDA approval.The launch of Neonorm Dog is intended to broaden Jaguar's commercial footprint in the companion animal market and extend consumer awareness of the Neonorm brand. Dogs represent one of the largest companion animal populations in the United States and Europe, and Jaguar believes Neonorm Dog may create an opportunity to reach pet o...